189 related articles for article (PubMed ID: 24302484)
1. Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations.
Mikati AG; Tan H; Shenkar R; Li L; Zhang L; Guo X; Larsson HB; Shi C; Liu T; Wang Y; Shah A; Edelman RR; Christoforidis G; Awad I
Stroke; 2014 Feb; 45(2):598-601. PubMed ID: 24302484
[TBL] [Abstract][Full Text] [Related]
2. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.
Girard R; Fam MD; Zeineddine HA; Tan H; Mikati AG; Shi C; Jesselson M; Shenkar R; Wu M; Cao Y; Hobson N; Larsson HBW; Christoforidis GA; Awad IA
J Neurosurg; 2017 Jul; 127(1):102-110. PubMed ID: 27494817
[TBL] [Abstract][Full Text] [Related]
3. Vascular permeability in cerebral cavernous malformations.
Mikati AG; Khanna O; Zhang L; Girard R; Shenkar R; Guo X; Shah A; Larsson HB; Tan H; Li L; Wishnoff MS; Shi C; Christoforidis GA; Awad IA
J Cereb Blood Flow Metab; 2015 Oct; 35(10):1632-9. PubMed ID: 25966944
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations.
Tan H; Zhang L; Mikati AG; Girard R; Khanna O; Fam MD; Liu T; Wang Y; Edelman RR; Christoforidis G; Awad IA
AJNR Am J Neuroradiol; 2016 Jul; 37(7):1209-15. PubMed ID: 26965464
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping.
Tan H; Liu T; Wu Y; Thacker J; Shenkar R; Mikati AG; Shi C; Dykstra C; Wang Y; Prasad PV; Edelman RR; Awad IA
Invest Radiol; 2014 Jul; 49(7):498-504. PubMed ID: 24619210
[TBL] [Abstract][Full Text] [Related]
6. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
Zeineddine HA; Girard R; Cao Y; Hobson N; Fam MD; Stadnik A; Tan H; Shen J; Chaudagar K; Shenkar R; Thompson RE; McBee N; Hanley D; Carroll T; Christoforidis GA; Awad IA
J Magn Reson Imaging; 2018 Apr; 47(4):1133-1138. PubMed ID: 28791783
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the venous angioarchitecture of multiple cerebral cavernous malformations with familial or sporadic disease: a susceptibility-weighted imaging study with 7-Tesla MRI.
Dammann P; Wrede K; Zhu Y; Matsushige T; Maderwald S; Umutlu L; Quick HH; Hehr U; Rath M; Ladd ME; Felbor U; Sure U
J Neurosurg; 2017 Feb; 126(2):570-577. PubMed ID: 27153162
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance Imaging of Mouse Cerebral Cavernomas Reveal Differential Lesion Progression and Variable Permeability to Gadolinium.
Fisher DG; Sharifi KA; Ulutas EZ; Kumar JS; Kalani MYS; Miller GW; Price RJ; Tvrdik P
Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):958-970. PubMed ID: 37078284
[TBL] [Abstract][Full Text] [Related]
9. Association of cardiovascular risk factors with disease severity in cerebral cavernous malformation type 1 subjects with the common Hispanic mutation.
Choquet H; Nelson J; Pawlikowska L; McCulloch CE; Akers A; Baca B; Khan Y; Hart B; Morrison L; Kim H
Cerebrovasc Dis; 2014; 37(1):57-63. PubMed ID: 24401931
[TBL] [Abstract][Full Text] [Related]
10. Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.
Lanfranconi S; Scola E; Bertani GA; Zarino B; Pallini R; d'Alessandris G; Mazzon E; Marino S; Carriero MR; Scelzo E; Faragò G; Castori M; Fusco C; Petracca A; d'Agruma L; Tassi L; d'Orio P; Lampugnani MG; Nicolis EB; Vasamì A; Novelli D; Torri V; Meessen JMTA; Al-Shahi Salman R; Dejana E; Latini R;
Trials; 2020 May; 21(1):401. PubMed ID: 32398113
[TBL] [Abstract][Full Text] [Related]
11. A rupture risk analysis of cerebral cavernous malformation associated with developmental venous anomaly using susceptibility-weighted imaging.
Zhang S; Ma L; Wu C; Wu J; Cao Y; Wang S; Zhao J
Neuroradiology; 2020 Jan; 62(1):39-47. PubMed ID: 31482190
[TBL] [Abstract][Full Text] [Related]
12. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).
Girard R; Li Y; Stadnik A; Shenkar R; Hobson N; Romanos S; Srinath A; Moore T; Lightle R; Shkoukani A; Akers A; Carroll T; Christoforidis GA; Koenig JI; Lee C; Piedad K; Greenberg SM; Kim H; Flemming KD; Ji Y; Awad IA
Neurosurgery; 2021 Feb; 88(3):686-697. PubMed ID: 33469662
[TBL] [Abstract][Full Text] [Related]
13. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling.
Hage S; Kinkade S; Girard R; Flemming KD; Kim H; Torbey MT; Huang J; Huston J; Shu Y; Selwyn RG; Hart BL; Mabray MC; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar-Felix RJ; Shenkar R; Hobson N; DeBiasse D; Lane K; McBee NA; Treine K; Ostapkovich N; Wang Y; Thompson RE; Koenig JI; Carroll T; Hanley DF; Awad IA
Stroke; 2024 Jan; 55(1):31-39. PubMed ID: 38134265
[TBL] [Abstract][Full Text] [Related]
14. Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth.
Sone JY; Hobson N; Srinath A; Romanos SG; Li Y; Carrión-Penagos J; Shkoukani A; Stadnik A; Piedad K; Lightle R; Moore T; DeBiasse D; Bi D; Shenkar R; Carroll T; Ji Y; Girard R; Awad IA
J Magn Reson Imaging; 2022 May; 55(5):1440-1449. PubMed ID: 34558140
[TBL] [Abstract][Full Text] [Related]
15. Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease.
Girard R; Zeineddine HA; Orsbon C; Tan H; Moore T; Hobson N; Shenkar R; Lightle R; Shi C; Fam MD; Cao Y; Shen L; Neander AI; Rorrer A; Gallione C; Tang AT; Kahn ML; Marchuk DA; Luo ZX; Awad IA
J Neurosci Methods; 2016 Sep; 271():14-24. PubMed ID: 27345427
[TBL] [Abstract][Full Text] [Related]
16. Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project.
Kim H; Flemming KD; Nelson JA; Lui A; Majersik JJ; Cruz MD; Zabramski J; Trevizo O; Lanzino G; Zafar A; Torbey M; Mabray MC; Robinson M; Narvid J; Lupo J; Thompson RE; Hanley DF; McBee N; Treine K; Ostapkovich N; Stadnik A; Piedad K; Hobson N; Carroll T; Shkoukani A; Carrión-Penagos J; Mendoza-Puccini C; Koenig JI; Awad I
Stroke; 2021 Dec; 52(12):3829-3838. PubMed ID: 34525838
[TBL] [Abstract][Full Text] [Related]
17. Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation.
Koskimäki J; Polster SP; Li Y; Romanos S; Srinath A; Zhang D; Carrión-Penagos J; Lightle R; Moore T; Lyne SB; Stadnik A; Piedad K; Cao Y; Shenkar R; Dimov AV; Hobson N; Christoforidis GA; Carroll T; Girard R; Awad IA
Geroscience; 2020 Oct; 42(5):1351-1363. PubMed ID: 32556941
[TBL] [Abstract][Full Text] [Related]
18. Cerebral cavernous malformations: Typical and atypical imaging characteristics.
Kuroedov D; Cunha B; Pamplona J; Castillo M; Ramalho J
J Neuroimaging; 2023 Mar; 33(2):202-217. PubMed ID: 36456168
[TBL] [Abstract][Full Text] [Related]
19. Cerebral Cavernous Malformations, Developmental Venous Anomaly, and Its Coexistence: A Review.
Idiculla PS; Gurala D; Philipose J; Rajdev K; Patibandla P
Eur Neurol; 2020; 83(4):360-368. PubMed ID: 32731220
[TBL] [Abstract][Full Text] [Related]
20. Advanced magnetic resonance imaging of cerebral cavernous malformations: part I. High-field imaging of excised human lesions.
Shenkar R; Venkatasubramanian PN; Zhao JC; Batjer HH; Wyrwicz AM; Awad IA
Neurosurgery; 2008 Oct; 63(4):782-9; discussion 789. PubMed ID: 18981890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
